American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
March 31, 2026
What were the key takeaways from American Shared Hospital Services's March 31, 2026 earnings call?
In the fourth quarter of 2025, American Shared Hospital Services (AMS) reported total revenue of $7.7 million, a decline of 14.8% year-over-year, primarily due to the expiration of three Gamma Knife contracts and lower proton beam radiation therapy volumes. For the full year, total revenue was $28.1 million, slightly down from $28.3 million in 2024, with a net loss of $1.6 million or $0.23 per diluted share. Management highlighted a strategic shift towards direct patient care, which now constitutes 63% of total revenue, and expressed optimism for 2026, signaling ongoing improvements in treatment volumes and operational efficiencies.
What topics did American Shared Hospital Services cover?
- Revenue Decline: AMS experienced a significant revenue decline of 14.8% in Q4 2025, attributed to the expiration of three Gamma Knife contracts and lower proton beam therapy volumes. Management stated, "This decline was primarily driven by the expiration of 3 Gamma Knife contracts and lower proton beam radiation therapy volumes."
- Shift to Direct Patient Care: The company is transitioning towards a direct patient care model, which now accounts for 63% of total revenue, reflecting a 2.6% year-over-year increase. Management noted, "Our strategy is centered on building and leveraging strong partnerships with leading health systems."
- Operational Challenges: AMS faced operational challenges including physician turnover and reimbursement dynamics, which management addressed through strategic partnerships and operational improvements. They mentioned, "We encountered challenges across certain areas of our business, including physician turnover, reimbursement dynamics and expected headwinds in our Leasing segment."
- International Expansion: The company is expanding its international footprint, with successful operations in Puebla, Mexico, and plans for a new center in Guadalajara. Management stated, "We see significant opportunity in international markets, including the development of our Guadalajara, Mexico center, which we expect to begin operations in 2026."
- Financial Position and Debt: AMS is actively engaged with lenders to enhance its capital structure amidst challenges in meeting financial covenants. The management indicated, "We are in active and constructive discussions with our lender regarding amendments and potential restructuring of our credit facility."
What were American Shared Hospital Services's March 31, 2026 results?
- Q4 Revenue: $7.7 million (vs $9.1 million in Q4 2024, -14.8% YoY)
- Full Year Revenue: $28.1 million (vs $28.3 million in 2024, -0.7% YoY)
- Net Loss: $1.6 million (or $0.23 per diluted share, vs net income of $2.2 million in 2024)
- Adjusted EBITDA: $5.5 million (vs $8.9 million in 2024)
- Direct Patient Care Revenue: $15.5 million (up 23.7% YoY)
- LINAC Revenue: $11.5 million (up 35.4% YoY)
The earnings call highlighted significant operational challenges and a strategic shift towards direct patient care, which could stabilize revenue in the long term. However, the immediate outlook is clouded by declining revenues and increased operational costs. Investors should monitor the company's progress in expanding treatment volumes and addressing financial covenant issues as potential catalysts for recovery.
Earnings Call Speaker Segments
Kirin Smith
executiveThanks, Chuck, and I appreciate all of you being with us today. Before the market opened this morning, AMS put out its earnings press release covering the fourth quarter and the full year 2025. Should you want a copy, you'll find it on the company's website, www.ashs.com, listed under Press Releases within the Investors tab. Ahead of handing the call to management, I want to offer a few comments regarding forward-looking statements. Be aware that any number of things that might be said during this conference call regarding future expectations, plans and prospects for the company count as forward-looking statements for the purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, owing to various important factors, among them those covered in the company's filings with the SEC, including our annual report on Form 10-K for the year ended December 31, 2025. No obligation is assumed by the company to update the information contained in this conference call. Before I hand the call to management, let me remind everybody about our Q&A policy: each participant gets the time to ask one question and one follow-up. As always, we'll gladly take additional questions offline at any time. With that, I'd now like to turn the call over to Ray Stachowiak, Executive Chairman. Ray, please go ahead.
Ray Stachowiak
executiveThanks, Kirin, and good afternoon to all of you. When I look back at 2025, I think about how strong and how vital our partnerships with health systems are — they remain the bedrock of what we do and a major force behind our long-term strategy. During the last year, we collaborated intently with partners both new and of long standing to get our company ready to thrive in 2026 and afterward. Through these alliances, we've been able to broaden our clinical reach, reinforce how we operate, and give more patients access to sophisticated cancer care. 2025 brought transition and investment. Our total revenue held fairly steady at $28.1 million, yet the change happening beneath the surface of our business was considerable. We kept pushing our sea change toward a direct patient care model, which today accounts for most of our revenue and offers a steadier, more scalable platform for growth over the long term. Simultaneously, we ran into difficulties in some parts of our business, among them physician turnover, reimbursement dynamics, and anticipated headwinds in our leasing segment. Crucially, we acted decisively to tackle every one of these matters. One of the year's standout moments was the fortifying of our partnerships, among them our new collaboration with Brown University Health in Rhode Island, which has aided us in rebuilding our physician base and boosting treatment volumes. We're also delighted to be able to report that our long-standing relationship with Orlando Health has been extended by a seven year lease extension for our proton beam radiation therapy system. I want to call attention to our long-standing partnership of over two decades with Orlando Health, which plainly illustrates how enduring our relationships are and mirrors the continuing collaboration in delivering advanced cancer treatment services. Beyond that, as part of our wider effort to shore up our financial position, we're actively engaged with our lending partners as we weigh opportunities to improve our capital structure and back our long-term growth initiatives. Our ties with our lenders go back a long way, and these conversations are constructive and ongoing. Looking forward, we believe we've established a solid foundation for future growth, bolstered by new and old partnerships, expanded clinical capacity, and a clear development pipeline; with that, I'll hand the call over to Gary. Gary?
Gary Delanois
executiveThank you, Ray, and hello to everyone joining this afternoon. For American Shared Hospital Services, 2025 served as a year that laid the groundwork, during which we grew our platform for direct patient care services and reinforced the operational backbone required to sustain growth over the long term. At the heart of our approach lies the creation and utilization of robust collaborations with top-tier health systems, and across the year we achieved substantial headway on that objective; throughout Rhode Island, we collaborated intensively with Brown University Health, Care New England and CharterCARE Health Partners in order to steady and reconstruct our team of radiation oncology physicians. Thanks to that work, our physician staffing is now on stable footing, and treatment volumes are starting to show gains, which we anticipate carrying forward into 2026. We likewise made key moves to bolster how we operate, among them upgrades to the infrastructure behind our revenue cycle management. That affords us tighter oversight of billing and collections and puts us in position to enhance financial results as time goes on. Regarding expansion, our segment for direct patient care services grew considerably, propelled by a complete year of activity at our Rhode Island sites along with our facility in Puebla, Mexico. Those sites are broadening patient access to sophisticated radiation therapy options and sit at the core of our strategy for growth over the long haul. On top of that, LINAC treatments posted robust gains, with volumes climbing markedly compared with the prior year, mirroring the input from our Rhode Island and Puebla sites. Meanwhile, Gamma Knife volumes rose at the same-center level after technology upgrades, whereas proton therapy treatment volumes showed fluctuation. Our operations abroad remain a powerful contributor and a substantial wellspring of future potential. During 2025, we completed the relocation of our Lima, Peru site and brought our Gamma Knife up to a cutting-edge Esprit platform; we keep turning in solid results in Puebla, which has surpassed what we anticipated, and we hold leading positions in Ecuador and Peru with the sole Gamma Knife centers operating in each of those nations. Looking forward, we perceive considerable potential across international markets, among them the build-out of our Guadalajara, Mexico site, which should start operating in 2026. In Rhode Island, we have likewise established a distinct path for growth via our certificate of need approvals covering both a fresh radiation therapy treatment center in Bristol and a proton beam radiation therapy center in Johnston. These undertakings stand as key long-term growth catalysts and further reinforce our ties with premier health systems across the area. On the operational and financial side, we are concentrating as well on bolstering the business's overall foundation, among other things by enhancing cash flow generation and bringing our cost structure into line with the size of our operations. As Ray noted, we are collaborating closely with our lending partners while we keep putting capital into the business and readying the company for long-term growth. We hold the view that the operational measures we are taking will underpin these efforts and boost our financial flexibility as time passes. Although 2025 brought operational difficulties, we tackled them head-on and made the investments required to ready the company for better results. Our priorities ahead are unambiguous. We can grow the number of treatments at the centers we already operate, push for better operational efficiency and improved margins, broaden our footprint via careful development, and keep using our partnerships to scale the platform. Given the base we have established, we feel positive about 2026 and sure of our growth path over the long term. So now, I'll hand things over to Scott.
Scott Frech
executiveThanks, Gary, and good afternoon to all of you. I'd like to start by walking through what we saw in the fourth quarter, and then I'll take you through how we performed across the entirety of 2025 along with the main financial factors behind those results. Looking at Q4, total revenue came in at $7.7 million, which was down 14.8% from the $9.1 million we recorded in the same period a year earlier. The main reasons for that drop were the conclusion of three Gamma Knife contracts as well as softer volumes in proton beam radiation therapy. Our direct patient care service segment accounted for 63% of overall revenue, and it grew 2.6% compared with the prior year to reach $4.8 million, largely on the strength of more procedures performed at our facility in Puebla, Mexico as well as in Rhode Island. Meanwhile, revenue from medical equipment leasing fell 33.9% to $2.9 million, which reflected both weaker PBRT volumes and the contracts that came to an end. Gross margin during the quarter stood at roughly $906,000, or 12%, versus 35% in Q4 2024, as a result of both reduced treatment volumes and the ongoing change in our revenue mix toward direct patient services. Net loss attributable to the company narrowed to $631,000, or $0.09 per diluted share, compared with a net loss of $1.6 million, or $0.23 per diluted share, in the same period last year. Adjusted EBITDA for the quarter was $868,000, versus $3.8 million in Q4 2024. On a full-year basis, total revenue reached $28.1 million, compared with $28.3 million in 2024. Direct patient care services revenue rose 23.7% to $15.5 million, while leasing revenue dropped to $12.6 million, which reflects the strategic transition the company continues to make. To give you some added context, LINAC revenue climbed 35.4% to $11.5 million, Gamma Knife revenue was down 5.5% to $9.2 million, and proton beam radiation therapy revenue fell 26% to $7.4 million. LINAC treatment sessions more than doubled, reaching 28,147 in 2025, which was the first full year of operations for both Puebla and Rhode Island. Gross margin for the year came to $5.1 million, or 18% of revenue, compared with $9.2 million in 2024, which reflects higher operating costs as well as reduced contributions from the leasing segment. The net loss attributable to our company was $1.6 million, or $0.23 per diluted share, versus net income of $2.2 million in 2024, a figure that included a $3.8 million bargain purchase gain tied to the Rhode Island acquisition. Adjusted EBITDA for the full year was $5.5 million, compared with $8.9 million in 2024. Now let me turn to the balance sheet. We finished the year with roughly $3.7 million in cash, down from $11.3 million at the close of 2024. That decline was mainly the result of $7.5 million in capital expenditures tied to our Rhode Island expansion and our international investments. Total debt at year-end was approximately $17.3 million, mostly connected to our credit facilities. As we've noted before, certain financial covenants were not satisfied at year-end because of weaker profitability during our transition, higher operating costs, and smaller leasing contributions. We're currently engaged in active and constructive conversations with our lender about amendments and a possible restructuring of our credit facility. Given those discussions, we believe we'll get to an agreement that gives us the flexibility we need to support our business plan. Although unresolved, such circumstances create significant uncertainty regarding whether we can keep operating as a going concern; even so, given our continued work with lenders and better operational results, we feel assured about where we are headed. Last, please note that on December 31st, 2025, shareholder equity, with non-controlling interests included, stood at $24 million, equal to $3.66 for each share outstanding, versus $25.2 million, or $3.92 for each share outstanding, on December 31st, 2024. Compared with what the market currently values us at, we want to draw attention to how deeply our market value is discounted. That brings the financial review to a close. I will now hand the call back for Q&A.
Marla Marin
analystThanks. From what you've said, and from what we've observed, it looks obvious that upgrading equipment pays off over time, yet near term you get a short-lived distortion, since lacking that equipment, well, throws off the ability to compare one year with the next. To start, I appreciate your giving us a few same center volumes. That helps, I think. That was a roundabout way of asking this: as your footprint gets deeper in Rhode Island, could referring patients between centers let you cancel out part of that noise? Or can that simply not be managed without much trouble?
Gary Delanois
executiveWell, I appreciate the question. In Rhode Island, that absolutely forms one piece of the strategy. You know, after the infrastructure we've got gets set up, we can take that infrastructure and apply it across a wider footprint. Economies of scale come into it, and that absolutely makes up one piece of how we're pursuing regional development across Rhode Island.
Marla Marin
analystAll right, that's helpful. Thank you. I have one more question. Could you go over again when the first new Rhode Island center is expected to be built, and equally important, how far ahead of opening day do you start hiring and preparing staff for it?
Gary Delanois
executiveOur expectation is that the Bristol site becomes operational toward the end of 2027, with the proton center arriving after it in 2028. On the hiring side, our practice is to begin bringing people on board a number of months ahead of time. That, once more, is among the benefits we enjoy; we have, say, a group of radiation therapists, physicists, dosimetrists, and physicians whom we can deploy across that period, particularly during the earliest phase or the initial buildup, which lets us keep a very tight grip on our costs. Whenever more staff members are required, we will bring them in gradually as patient volumes grow.
Marla Marin
analystCan I quickly slip in one more question? Is it fair to read that as meaning there won't be much idle time for a number of the professional staffing folks, given how long it takes from hiring someone to actually getting the facility open, plus the chance to use some of those people at other locations?
Gary Delanois
executiveYes, that's right.
Marla Marin
analystOkay. Thank you.
Gary Delanois
executiveThank you.
Tony Marchese
analystYes. Hey, everyone. I have a question about those 3 contracts that lapsed. Were you aware of them during the prior earnings call? I'm attempting to understand why, you know, why it keeps catching us off guard with, oh, revenue came in lower for this quarter since, you know, contracts ran out. Shouldn't that typically be something you'd disclose to investors if you're aware those agreements are ending?
Gary Delanois
executiveRay, let me turn to you, just for context from history and from other calls, regarding what we share about contracts that expire; there were 3, and in each of those situations, they were centers, health systems that wanted to, essentially, chose to handle the upgrade on their own instead of using us for that portion of funding their capital expenditure.
Ray Stachowiak
executiveYeah, Tony, I think we've.
Gary Delanois
executiveThey did continue.
Ray Stachowiak
executiveTony, my sense is that nothing fresh is actually coming to light in this. We've talked about it during earlier calls and in prior disclosures. As you're aware, once you look at a fourth quarter — okay, 2025 versus 2024 — well, if those deals lapsed during the third quarter of 2024, then comparing the entire year will show you negative variances. Should they have lapsed in first quarter of 2025, then pitting fourth quarter of 2024 against fourth quarter of 2025 will produce negative variances for you. My view is that we've stayed fairly consistent on this. No genuinely new contracts are running out; there is one, though it involves low technology, and we're more or less simply letting it stay extended at low volumes. That scenario carries little to no cost.
Tony Marchese
analystUnderstood. Alright, my next question — are you expecting to be profitable across all of 2025, pardon me, 2026?
Ray Stachowiak
executiveGary, I'll handle that one.
Gary Delanois
executiveYes, go ahead and please take it. Yep.
Ray Stachowiak
executiveRight, Tony, that's not something we can speculate about. Providing forward-looking statements has never been our practice. That's just not something we can comment on.
Tony Marchese
analystGot it.
Ray Stachowiak
executiveYou know, we had.
Tony Marchese
analystAll right.
Ray Stachowiak
executiveThe problems at the foundation — those have been dealt with. We've taken care of them.
Tony Marchese
analystUnderstood. My guess is that the credit agreement you have, or perhaps one you're putting forward or would sign at some stage — ideally before long — would it stop you folks from repurchasing shares?
Gary Delanois
executiveTony, would you mind repeating that question? I'm not certain.
Tony Marchese
analystOh, my apologies. What I'm getting at is whether your capacity to repurchase shares is limited by some lending arrangement, or if it's simply a choice you folks have made that you don't want to do buybacks? What I'm driving at is that you're going out of your way to point out that shares trade at 50% of book value, yet there's no repurchase program, and your board members essentially hold no shares. I mean, 2 directors hold 2,000 shares, and 1 director holds none. I don't see much of, and I apologize for being this blunt, but from an investor's standpoint, I want to see the board having skin in the game alongside shareholders. Honestly, 3 of your board members hold essentially no shares, so my question is, if they won't purchase stock and demonstrate faith in the business, maybe the company should show investors some confidence by repurchasing shares. I'm simply asking, could that happen, or are you prevented from doing buybacks due to other considerations?
Ray Stachowiak
executiveYeah. Gary, I'll take that.
Gary Delanois
executiveYou've addressed this on prior calls, and I'll turn it over to him.
Ray Stachowiak
executiveYes. I appreciate you asking that. Historically, this company hasn't shown much appetite for repurchasing shares or establishing a stock buyback plan. Given where things stand with our lenders right now, that position probably won't shift. As for me, my alignment hasn't wavered. My confidence in this business remains very strong. I'm aware our share price hasn't done well, and having to announce a loss for a year is tough to take, yet my optimism about where this company is headed stays just as high.
Tony Marchese
analystNo, I realize that's true about you. Absolutely. 100%. I'm aware of it. There have been calls between us, including private ones. I know that's who you are. What I think would be useful — and this is all I'll say about it — I'm not attempting to make some last stand over this remark, if you will, but the thing I'm driving at is this: it would genuinely help and would signal confidence if the three board members who hold essentially no shares would come forward and make a purchase. After all, you're paying each of them $50,000 annually in compensation. Perhaps, as a means of keeping cash on hand or stretching how far your cash can go, you could think about asking them to receive that pay as stock rather than in cash, which in my view would help bring their interests into line with my own. That's all I have to say.
Ray Stachowiak
executiveYeah. Yeah. I believe that's been duly noted; we'll take that under consideration, Tony.
Tony Marchese
analystAlright, thanks.
Gary Delanois
executiveAnd Gary Delanois here — appreciate you asking, Tony.
Gary Delanois
executiveChuck, thanks, and I appreciate everyone being here with us today. During 2025, we established the groundwork for the growth we expect ahead. By building solid partnerships, increasing our clinical capacity, and making focused operational enhancements, we got the company ready for the next stage of its development. Although we faced difficulties over the course of the year, we acted decisively to resolve them, and those efforts are already paying off. With a stronger management team, an expanding direct patient care services platform, and a solid development pipeline, we feel good about 2026 and the years after. Our attention stays on providing high-quality cancer care, broadening patient access via the advanced treatment technologies, and generating long-term value for our shareholders. Thanks once more for your ongoing support and interest in American Shared Hospital Services.
Operator
operatorThat brings this call to a close. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.